Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD’s annual review of adverse events published
The number of safety (adverse reaction) reports increased in only two major species, dogs and sheep.

Report highlights rise in suspected lack of efficacy reports for cats

The Veterinary Medicines Directorate (VMD) has published its annual review of adverse events in animals, humans and the environment after the use of veterinary medicines.

The Veterinary Pharmacovigilance in the United Kingdom review summarises 6,721 UK adverse events reported to the VMD in 2017, an increase of 2.5 per cent on the previous year, compared to 15 per cent from 2015 to 2016.

Of the reports received, dogs were the only major species that had increased (9%). The largest decrease was for rabbits, with a fall of more than 31 per cent.

The report also highlights a considerable rise in the number of suspected lack of expected efficacy reports for cats compared to 2016. These were for products that affect the nervous system, including general anaesthetics, sedatives and analgesics.

Products for reversal of sedation also increased, as did combined treatments for the prevention of infestation by international and external parasites.

The number of safety (adverse reaction) reports increased in only two major species, dogs and sheep. The increase in dogs was owing to reports involving medicines for treating the intestines, heart and circulation, the nervous system and the ears.

Half of the products involved in sheep safety cases were anti-parasitics, with 50 per cent of those being wormers. 

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.